Difference between revisions of "Capecitabine (Xeloda)"
Jump to navigation
Jump to search
m (Text replace - "package insert<ref name="insert"></ref>." to "prescribing information.<ref name="insert"></ref>") |
(updated content) |
||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Pyrimidine analog, antimetabolite, inhibitor of thymidylate synthase. Converted in vivo to [[fluorouracil (5-FU)]], which is metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis by binding to thymidylate synthase and inhibiting production of thymidylate; FUTP interferes with RNA processing when it is mistakenly incorporated in place of uridine triphosphate (UTP).<ref name="insert">[http://www.gene.com/gene/products/information/xeloda/pdf/pi.pdf Capecitabine (Xeloda) package insert]</ref><ref>[ | + | Class/mechanism: Pyrimidine analog, antimetabolite, inhibitor of thymidylate synthase. Converted in vivo to [[fluorouracil (5-FU)]], which is metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis by binding to thymidylate synthase and inhibiting production of thymidylate; FUTP interferes with RNA processing when it is mistakenly incorporated in place of uridine triphosphate (UTP).<ref name="insert">[http://www.gene.com/gene/products/information/xeloda/pdf/pi.pdf Capecitabine (Xeloda) package insert]</ref><ref>[[Media:Capecitabine.pdf | Capecitabine (Xeloda) package insert (locally hosted backup)]]</ref><ref>[http://www.xeloda.com/ Xeloda manufacturer's website]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content |
| + | /search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> | ||
| + | |||
| + | ==Diseases for which it is used== | ||
| + | *[[Breast cancer]] | ||
| + | *[[Colon cancer]] | ||
| + | *[[Esophageal cancer]] | ||
| + | *[[Hepatobiliary cancer]] | ||
| + | *[[Pancreatic cancer]] | ||
| + | *[[Rectal cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[http://chemocare.com/ | + | *[http://www.gene.com/gene/products/information/xeloda/pdf/pi.pdf#page=34 Capecitabine (Xeloda) package insert pages 34-37]<ref name="insert"></ref> |
| + | *[http://chemocare.com/chemotherapy/drug-info/capecitabine.aspx Capecitabine (Xeloda) patient drug information (Chemocare)]<ref>[http://chemocare.com/chemotherapy/drug-info/capecitabine.aspx Capecitabine (Xeloda) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/capecitabine-patient-drug-information Capecitabine (Xeloda) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/capecitabine-patient-drug-information Capecitabine (Xeloda) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/capecitabine-patient-drug-information Capecitabine (Xeloda) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/capecitabine-patient-drug-information Capecitabine (Xeloda) patient drug information (UpToDate)]</ref> | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Nucleic acid analogs]] | ||
| + | [[Category:Breast cancer medications]] | ||
| + | [[Category:Colon cancer medications]] | ||
| + | [[Category:Esophageal cancer medications]] | ||
| + | [[Category:Hepatobiliary cancer medications]] | ||
| + | [[Category:Pancreatic cancer medications]] | ||
| + | [[Category:Rectal cancer medications]] | ||
Revision as of 04:21, 8 October 2012
General information
Class/mechanism: Pyrimidine analog, antimetabolite, inhibitor of thymidylate synthase. Converted in vivo to fluorouracil (5-FU), which is metabolized to 5-fluoro-2'-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). FdUMP inhibits DNA synthesis by binding to thymidylate synthase and inhibiting production of thymidylate; FUTP interferes with RNA processing when it is mistakenly incorporated in place of uridine triphosphate (UTP).[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, [http://www.utdol.com/online/content /search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Capecitabine (Xeloda) package insert pages 34-37[1]
- Capecitabine (Xeloda) patient drug information (Chemocare)[4]
- Capecitabine (Xeloda) patient drug information (UpToDate)[5]